Plain-English translation of NCT07727642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether long-acting injectable HIV medications—such as or —work better than traditional oral HIV pills for people who have both HIV and a type of cancer called AIDS-related lymphoma. The research team will compare three different approaches to HIV treatment while you receive standard cancer therapy, to see which one best controls your HIV and keeps you healthy during your lymphoma care.
People with both HIV and lymphoma face a special challenge: their cancer treatment can make HIV harder to control, and some HIV medications may interfere with cancer drugs. This study is trying to find out whether the newer, long-acting medications offer better HIV control and safety during the months when you're being treated for lymphoma.
You likely qualify if…
You likely don't qualify if…
You will receive one of three HIV treatment strategies based on your medical condition and preference, while continuing your standard lymphoma treatment. You'll visit the clinic at baseline and then at weeks 4, 8, 12, 24, 36, and 48 for blood tests to measure your HIV levels and immune health, along with safety checks. The study lasts 48 weeks (about one year) and involves regular blood work and clinic visits to monitor how well the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
China